Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista mexicana de urología
versión On-line ISSN 2007-4085versión impresa ISSN 0185-4542
Resumen
RAMIREZ-SEVILLA, Cristóbal; GOMEZ-LANZA, Esther y PUYOL-PALLAS, Josep-Miquel. Behavior of MV140 vaccine to prevent recurrent urinary tract infections in patients with metabolic syndrome and smoking. Rev. mex. urol. [online]. 2022, vol.82, n.6, e02. Epub 20-Mar-2023. ISSN 2007-4085. https://doi.org/10.48193/revistamexicanadeurologa.v82i6.959.
Introduction:
This study analyzed patients with metabolic syndrome and smokers treated with MV140 vaccine to prevent recurrent UTI.
Material and methods:
342 patients with recurrent UTI received MV140 vaccine between 2017 and 2020 in Barcelona, Spain. Variables analyzed: number of UTI at 3 and 6 months after MV140, age, gender, diabetes mellitus, body mass index, hypertension, total cholesterol, HDL-cholesterol, triglycerides and smoking. Patients were divided in Group 1: metabolic syndrome (2 or more variables), Group 2: no metabolic syndrome (less than 2 variables). On the other hand, patients were classified into smokers and non-smokers.
Results:
Mean age was 74, 82% were women. At the beginning, 88,9% had 3-5 UTI. Overall effectiveness with MV140 was 72.5% at 3 months and 56.2% at 6 months.
Group 1 (36%) presented 0-1 UTI in 78.9% and 62.6% at 3 and 6 months. In Group 2 (64%) the results were 69% and 52.5%. Comparing both groups, no statistically significant differences were observed (p=0,25, p=0,26). Smokers had 77.4% and 61.3% at 3 and 6 months, and non-smokers had 69.3% and 52.7%. There were also no statistically significant differences (p = 0.5, p = 0.36).
Group 1 and smoking (28,7%) had 82% at 3 months and 66.3% at 6 months. Group 2 and no smoking (71,3%) reached 60.3% and 52% at 3 and 6 months. There were no statistically significant differences between both groups.
Conclusions:
The overall efficacy of MV140 was high and safe, without side effects.
Patients with metabolic syndrome and smokers may benefit from this treatment.
Palabras llave : Recurrent urinary tract infections; inmunoprophylaxis; MV140 vaccine; metabolic syndrome; smoking.